# Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)

> **NCT05012280** · — · TERMINATED · sponsor: **Institute of Tropical Medicine, Belgium** · enrollment: 238 (actual)

## Conditions studied

- Covid19
- Paludism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05012280
- **Lead sponsor:** Institute of Tropical Medicine, Belgium
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-04
- **Primary completion:** 2022-08-17
- **Final completion:** 2022-08-17
- **Target enrollment:** 238 (ACTUAL)
- **Why stopped:** As the COVID-19 epidemic evolved, presentation of the disease changed substantially.

Due to vaccination, increased natural immunity and new variants, there is a substantial decrease in severe cases, making it difficult to recruit new patients.
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012280, "Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05012280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*